Sugi Predict

Sugi Predict / Compounds / SCHEMBL2653348

SCHEMBL2653348

SCHEMBL2653348

O=C(c1ccc(F)c(Cl)c1)N1CCCC1

nearest known ligand 0.73

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 5/20 0.73
▸ MAPT P10636 1/20 0.57
▸ HSD11B1 P28845 2/20 0.57
▸ ALDH1A1 P00352 1/20 0.56
▸ MEN1 O00255 2/20 0.55
▸ KMT2A Q03164 2/20 0.55
▸ NPBWR1 P48145 1/20 0.55
▸ MCHR1 Q99705 1/20 0.55
▸ PKM P14618 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ USP2 O75604 1/20 0.51
▸ PDK1 Q15118 2/20 0.51
▸ PDK2 Q15119 2/20 0.51
▸ PDK3 Q15120 2/20 0.51
▸ PDK4 Q16654 2/20 0.51
▸ HTR1A P08908 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2075037 0.97 HPGD (0.68) HPGDMAPTHSD11B1ALDH1A1MEN1
SCHEMBL22406684 0.87 HPGD (0.55) HPGDHSD11B1ALDH1A1MEN1KMT2A
SCHEMBL5630460 0.86 HPGD (0.54) HPGDHSD11B1ALDH1A1MEN1KMT2A
SCHEMBL4512607 0.86 HSD11B1 (0.58) HPGDMAPTHSD11B1MEN1KMT2A
SCHEMBL2655426 0.84 KMT2A (0.73) HPGDHSD11B1ALDH1A1MEN1KMT2A
SCHEMBL29944147 0.83 MEN1 (0.71) HPGDHSD11B1ALDH1A1MEN1KMT2A
SCHEMBL6280995 0.83 HPGD (0.96) HPGDMAPTHSD11B1ALDH1A1MEN1
Methane SCHEMBL7459255 0.82 HTR1A (0.57) HTR1A
SCHEMBL15499084 0.81 HPGD (0.75) HPGDMAPTHSD11B1ALDH1A1MEN1
SCHEMBL19971721 0.81 HTR1A (0.58) HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1756076-B1 HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES ASTRAZENECA AB (SE) 2010-08-11 — — EP disclosed
EP-1756076-B1 HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES ASTRAZENECA AB (SE) 2010-08-11 — — EP disclosed
US-7745475-B2 Such as 3-[(1S)-2-hydroxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide; glucokinases (Glk) ASTRAZENECA AB (SE) 2010-06-29 — — US disclosed
US-7745475-B2 Such as 3-[(1S)-2-hydroxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide; glucokinases (Glk) ASTRAZENECA AB (SE) 2010-06-29 — — US disclosed
US-7745475-B2 Such as 3-[(1S)-2-hydroxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide; glucokinases (Glk) ASTRAZENECA AB (SE) 2010-06-29 — — US disclosed
US-20090253676-A1 Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes ASTRAZENECA AB (SE) 2009-10-08 — — US disclosed
US-20090253676-A1 Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes ASTRAZENECA AB (SE) 2009-10-08 — — US disclosed
US-20090253676-A1 Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes ASTRAZENECA AB (SE) 2009-10-08 — — US disclosed
EP-1992623-A1 Heteroaryl benzamide derivative for use as GLK activator in the treatment of diabetes Astra Zeneca AB (SE) 2008-11-19 — — EP disclosed
EP-1992623-A1 Heteroaryl benzamide derivative for use as GLK activator in the treatment of diabetes Astra Zeneca AB (SE) 2008-11-19 — — EP disclosed
US-20080015203-A1 Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes ASTRAZENECA AB (SE) 2008-01-17 — — US disclosed
US-20080015203-A1 Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes ASTRAZENECA AB (SE) 2008-01-17 — — US disclosed
US-20080015203-A1 Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes ASTRAZENECA AB (SE) 2008-01-17 — — US disclosed
US-20070287693-A1 Benzamide Derivatives That Act Upon The Glucokinase Enzyme ASTRAZENECA AB (SE) 2007-12-13 — — US disclosed
EP-1802582-A1 BENZAMIDE DERIVATIVES THAT ACT UPON THE GLUCOKINASE ENZYME. AstraZeneca AB (SE) 2007-07-04 — — EP disclosed
EP-1756076-A1 HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES AstraZeneca AB (SE) 2007-02-28 — — EP disclosed
WO-2006040529-A1 BENZAMIDE DERIVATIVES THAT ACT UPON THE GLUCOKINASE ENZYME ASTRAZENECA AB (SE) 2006-04-20 — — WO disclosed
WO-2005121110-A1 HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES ASTRAZENECA AB (SE) 2005-12-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015203-A1 Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes GRK4, GRK5, GRK2 HPGD 595/4885MAPT 4885/4885HSD11B1 622/4885
US-20070287693-A1 Benzamide Derivatives That Act Upon The Glucokinase Enzyme GCK, GCKR, GRK4 HPGD 735/4885MAPT 4883/4885HSD11B1 1017/4885
US-20090253676-A1 Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes GRK4, GRK5, GRK2 HPGD 668/4885MAPT 4885/4885HSD11B1 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.